- Current report filing (8-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2009

ALLOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-29815	54-1655029
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

11080 CirclePoint Road, Suite 200 Westminster, Colorado		80020
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (303) 426-6262

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 — Other Events

Item 8.01 Other Events.

On December 8, 2009, Allos Therapeutics, Inc. issued a press release announcing updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press Release, dated December 8, 2009, entitled “Allos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-cell Lymphoma.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 8, 2009

		ALLOS THERAPEUTICS, INC.


	By:	/s/ Marc H. Graboyes
		Marc H. Graboyes
	Its:	Senior Vice President, General Counsel and Secretary

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release, dated December 8, 2009, entitled “Allos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-cell Lymphoma.”